Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Quisinostat

An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Histone deacetylases (HDACs) are a family of proteins whose main function is the removal of acetyl groups from lysine residues… Expand
Is this relevant?
2018
2018
Abstract Histone deacetylases (HDACs) are implicated in the pathology of various cancers, and their pharmacological blockade has… Expand
Is this relevant?
2017
2017
Abnormal epigenetic modifications are considered a main contributing factor to low cloning efficiency. In the present study, we… Expand
Is this relevant?
2016
2016
BACKGROUND Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor. OBJECTIVES To… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
The reversibility of non-genotoxic phenotypic changes has been explored in order to develop novel preventive and therapeutic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Abstract The maximum tolerated dose (MTD) of quisinostat + bortezomib + dexamethasone in patients with relapsed multiple myeloma… Expand
Is this relevant?
2015
2015
Histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) are in early clinical development for… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
BACKGROUND Quisinostat (JNJ-26481585) is a second-generation pyrimidyl-hydroxamic acid histone deacetylase (HDAC) inhibitor with… Expand
Is this relevant?
2014
2014
PURPOSE Uveal melanoma (UM) is fatal in up to 50% of patients because of liver metastases that are refractory to therapies… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?